FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine. Object 1 is a combination for treating a tumour in the biliary system, liver cancer, triple negative breast cancer or lung cancer, containing an anti-PD-L1 antibody and anlotinib. Objects 2 and 3 are a method of treating a tumour in the biliary system, liver cancer, thrice-negative breast cancer and/or lung cancer, involving administering to a subject an anti-PD-L1 antibody and anlotinib, including in the form of the above combination. Object 4 is a kit for treating a tumour in the biliary system, liver cancer, triple negative breast cancer and/or lung cancer, containing a pharmaceutical composition based on an anti-PD-L1 antibody, a pharmaceutical composition based on anlotinib.
EFFECT: synergistic antitumour effect of the combination of the anti-PD-L1 antibody and anlotinib on the tumour in the biliary system, in liver cancer, in triple-negative breast cancer, in lung cancer compared to any drug of the combination administered separately.
16 cl, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED DRUG FOR TREATING KIDNEY CANCER | 2021 |
|
RU2830590C2 |
| IL4R-BINDING ANTIBODIES AND USE THEREOF | 2021 |
|
RU2834713C1 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODY TO B7H3-EXATECAN ANALOGUE CONJUGATE AND ITS USE IN MEDICINE | 2019 |
|
RU2785664C2 |
| ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODY IN HETERODIMERIC FORM, SIMILAR IN STRUCTURE TO NATURAL ANTIBODY, AND PRODUCTION THEREOF | 2022 |
|
RU2825838C1 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
